suzhou, march 15, 2021 - alphamab oncology (stock code: 9966.hk) announced that dr. johannes nippgen, former head of r&d biopharma in china for merck, has joined the company as chief medical officer, reporting to dr. xu ting, chairman and ceo. dr. nippgen is responsible for clinical development and translational research. he will also contribute to r&d strategy and global cooperation.
dr. johannes nippgen joined the pharmaceutical industry over 15 years ago after another decade's experience as md/phd in clinical oncology. his industry expertise covers the clinical development and program leadership area in international biopharma and biotech companies. in his most recent position, he was heading r&d in china for the german merck. he studied clinical medicine in mainz, germany, and earned his doctorate in wurzburg, germany. he published in various regional and international journals including the new england journal of medicine.
dr. ting xu, chairman and ceo of alphamab oncology, commented, “we sincerely welcome dr. johannes nippgen to join the management at this key moment. i believe that dr. nippgen’s experience in clinical development and management will promote global expansion of alphamab and grow the company’s highly differentiated and innovative product pipeline. he will lead the critical clinical trials, both ongoing and planned, into next level and help make our innovation drugs available to patients around the world.”
dr. johannes nippgen commented, “alphamab oncology is an outstanding innovative company in the field of biopharmaceuticals in china. the company’s extraordinary independent innovation technology platform and global first-in-class potential product pipeline impressed me. dr. xu ting and i share a common scientific vision, are keen to continuously pursue innovation and are always committed to international cooperation. i am very happy to join this team with sense of mission and energy, and hope that through our joint efforts, we can give the world more innovative drugs, supporting clinical needs and benefiting patients all around the globe."
about alphamab oncology
alphamab oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.
alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a covid-19 multifunctional antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. the bla for envafolimab (kn035) has been accepted and granted priority review by the national medical products administration (nmpa).
the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of an european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
